Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance

Amneal Pharmaceuticals, Inc.

2025-Q1 EPS reported $0.04 revenue$695,420,000

Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).
Adjusted EBITDA $170M (+12% YoY); adjusted diluted EPS $0.21 (+50% from $0.14).
Affordable Medicines +6%, Specialty +3%, AvKARE +6%; CREXONT and injectable momentum cited.
Company reaffirms 2025 full-year guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.